Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2008
05/15/2008US20080114051 Pyrrolidine derivatives as prostaglandin modulators
05/15/2008US20080114050 Use of 5-(2-Cyano-5-pyrolyl)-2-indolinones for contraception; e.g. 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile; also use in hormone replacement therapy, dysmenorrhea, premenstrual syndrome, hormone-dependent cancers, uterine bleeding
05/15/2008US20080114049 (1S,6R)-6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane; use in therapy as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors
05/15/2008US20080114048 Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
05/15/2008US20080114047 Mycobacterium tuberculosis infection; protozoan pathogens; fungal pathogens; 2-((4-Amidinobenzofuran-2-yl)methyl)benzofuran-4-carboxamidine; 4,5-Dihydro-2-(2-(2-(5-(4,5-dihydro-1H-imidazol-2-yl)benzofuran-2-yl)ethyl)benzofuran-5-yl)-1H-imidazole
05/15/2008US20080114046 Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
05/15/2008US20080114045 Process for the Production of Candesartan
05/15/2008US20080114044 Isoxazole compounds as Peroxisome Proliferator-Activated Receptor (PPAR) delta modulators; (5-{4-[2-(2,4-Dichloro-phenoxy)-ethyl-carbamoyl]-5-phenyl-isoxazol-3-yl}-phenyl)-acetic acid; diabetes, cardiovascular disorders, dyslipidemias, irritable bowel disease, cancer, skin disorders, eye disorders
05/15/2008US20080114043 Medicinal Composition for Inhalation
05/15/2008US20080114042 Compound
05/15/2008US20080114041 Benzothiazolesulfonamides
05/15/2008US20080114040 Epothilone Derivatives
05/15/2008US20080114039 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; Cystic Fibrosis, Duchenne Muscular Dystrophy
05/15/2008US20080114038 Drugs Derived from Diclofenac Containing No-Donor Heterocycles, Composition and Method of Inflammation Treatment
05/15/2008US20080114037 Histone deacetylase inhibitors
05/15/2008US20080114036 Novel Compounds, Their Preparations And Use
05/15/2008US20080114035 Novel intermediate compounds useful in the preparation of oxazoles and pharmaceutical actives for the regulation of lipid and glucose metabolism
05/15/2008US20080114034 ethyl 1-benzyl-5-(3-carboxypropoxy)-2-methyl-6-pyrid-3-yl-1H-indole-3-carboxylate; peroxisome proliferator activated receptors agonist; dyslipidaemia, atherosclerosis, diabetes, obesity; high level lipoprotein controllong
05/15/2008US20080114033 N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent
05/15/2008US20080114032 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
05/15/2008US20080114031 1,2;5,6-Di-O-isopropylidene-3-deoxy-3-[{(4-chloro-phenyl)amino}-carbonyl]-amino- alpha -D-allofuranoside;
05/15/2008US20080114030 Diarymethyl and related compounds
05/15/2008US20080114029 Crystalline form of 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline; urinary antispasmodic
05/15/2008US20080114028 Combining solifenacin, succinic acid, and a solvent; urinary antispasmodic; selective antagonist to the M(3)-receptor
05/15/2008US20080114027 Postoperative delirium, sepsis associated delirium, and drug or alcohol withdrawal associated delirium; using ibudilast; kits
05/15/2008US20080114026 1-[4-(4-chloro-2-methyl-3H-imidazo[4,5-c]pyridin-3-ylmethyl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea; antitumor, antiinflammatory agent, autoimmune diseases; kinase signal transduction (tyrosine, Raf) mediated diseases: solid tumors, leukemia, psoriasis, arthritis, endometriosis,
05/15/2008US20080114025 Inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures; use of ADP receptor antagonist and a thromboxane A2 receptor antagonist
05/15/2008US20080114024 such as 5-(3-Aminopropylamino)-2-benzyloxy-7-(4-methoxyphenyl)-[1,6]naphthyridine; spleen tyrosine kinase inhibitor; controlling activation of mast cells; antiallergens, antiinflamamtory agents; asthma, chronic obstructive pulmonary disease (COPD), Crohn's disease, bronchitis, conjunctivitis, psoriasis
05/15/2008US20080114023 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
05/15/2008US20080114022 (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease
05/15/2008US20080114021 Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
05/15/2008US20080114020 Difluoro-Substituted Imidazopyridines
05/15/2008US20080114019 Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide
05/15/2008US20080114018 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
05/15/2008US20080114017 2-Methyl-1-thioxo-10-(3-trifluoromethoxy-phenyl)-1,2,3a,4,9,10-hexahydro-2,9,10a-triaza-cyclopenta[b]fluoren-3-one; anticarcinogenic agent; solid tumor and leukemia; cell-cycle specific mode of action: DNA replication or interfering directly with basic cellular molecules like DNA
05/15/2008US20080114016 5-(3-aminopropyl)-3-methyl-2,5,7,8,9,10-hexahydro-4H-benzo[g]pyrazolo[4,3-c]quinolin-4-one; anticarcinogenic agent; enhance DNA damaging agents by initiating mitosis before DNA repair is complete and thereby causing tumor cell death; in preparation of a anticancer medicaments
05/15/2008US20080114015 NF-kB inhibitors and uses thereof
05/15/2008US20080114014 Treating urinary and fecal incontinence in a patient being treated for a cognitive disorder consisting of one of a group of acute dementia and cognitive impairment by administration of a therapeutic amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist
05/15/2008US20080114013 Spiroindolinone derivatives
05/15/2008US20080114012 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease
05/15/2008US20080114011 Enhancement of Effectiveness of 5-Fluorouracil in Treatment of Tumor Metastases and Cancer
05/15/2008US20080114010 Novel Substituted Imidazole Compounds
05/15/2008US20080114009 Farnesyl Transferase Inhibiting 1,2-Annelated Quinoline Enantiomer
05/15/2008US20080114008 Quinazoline Derivatives as Antiviral Agents
05/15/2008US20080114007 8-indan-5-yl-5-oxo-2-(3-piperazin-1-yl-phenylamino)-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid isopropylamide; antiinflammatory, anticarcinogenic agent, cardiovascular disease; glomerulonephritis, immune nephritis, rheumatoid arthritis, asthma, pancreatitis, HIV infection, psoriasis
05/15/2008US20080114006 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies
05/15/2008US20080114005 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity
05/15/2008US20080114004 Hydrazone derivatives as kinase inhibitors
05/15/2008US20080114003 Pyrimidinylisoxazole Derivatives
05/15/2008US20080114002 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid
05/15/2008US20080114001 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-trifluoromethyl)phenyl]-benzamide; antitumor and antiproliferative agent, angiogenesis inhibitor; leukemia, myelodysplastic syndromes or pulmonary hypertension
05/15/2008US20080114000 Suppressor of excess accumulation of intracellular sodium ions
05/15/2008US20080113999 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States
05/15/2008US20080113997 Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
05/15/2008US20080113996 Treatment of renal diseases or conditions associated with abnormal ion flux in a mammal such as a human which comprises the administration of a hPPAR gamma modulator or salt or solvate thereof, such as farglitazar or rosiglitazone
05/15/2008US20080113995 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine; histamine-H3 receptor antagonist or inverse agonist; nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders
05/15/2008US20080113993 Barbituric acid analogs as therapeutic agents
05/15/2008US20080113992 Cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative, antitumor agent; leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases, arthritis, Alzheimer's disease
05/15/2008US20080113991 Pyridopyrazines and the use thereof as kinase inhibitors
05/15/2008US20080113990 Biphenyl derivatives as modulators of voltage gated ion channels
05/15/2008US20080113989 For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins
05/15/2008US20080113988 Isoxazoline-Indole Derivatives With an Improved Antipsychotic and Anxiolytic Activity
05/15/2008US20080113987 2-(2-methylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine; phosphatidylinositol 3-kinase (PI3K) inhibitor; transplantation of organs or tissues, inflammatory bowel diseases, psoriasis or atopic dermatitis, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis, scleroderma
05/15/2008US20080113986 such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide
05/15/2008US20080113985 Modulators of ATP-binding cassette transporters
05/15/2008US20080113984 3-Aryl-6-aryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
05/15/2008US20080113983 (N (R)-1-Azabicyclo[2.2.2]oct-3-yl)-3-fluoro-5-phenylthiophene-2-carboxylic acid amide; antidepressant, anxiolytic, analgesic agent, cognition activator, attention disorders
05/15/2008US20080113982 Azacyclosteroid histamine-3 receptor ligands
05/15/2008US20080113981 Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one
05/15/2008US20080113980 Substituted-2-imidazoles
05/15/2008US20080113978 Substituted imidazo[1,2-b]pyridazine compounds such as N-{4-chloro-5-[8-(1-ethyl-propyl)-2,6-dimethyl-imidazo[1,2-b]pyridazin-3-yl]-thiazol-2-yl}-morpholine; use as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases
05/15/2008US20080113977 For example, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline; for treating physiological disorders, particularly congestive heart disease
05/15/2008US20080113976 asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis; Azetidine-1-carboxylic acid {2-[({2-hydroxy-1-[(isopropyl-methyl-amino)-methyl]-pentylcarbamoyl}-methyl)-carbamoyl]-4-trifluoromethyl-phenyl}-amide
05/15/2008US20080113975 Thiourea compounds
05/15/2008US20080113974 Heterocyclic Oxime Compounds, A Process For Their Preparation And Pharmaceutical Compositions Containing Them.
05/15/2008US20080113973 Pharmaceutical composition in unit dose form which contains a COX-2 inhibitor and a thromboxane A2 receptor antagonist; for treatment of pain or inflammation; less risk of inducing adverse cardiovascular effects than when COX-2 inhibitors are administered alone
05/15/2008US20080113972 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis
05/15/2008US20080113971 improved potency; reduced undesirable side effects; pain, inflammation, arthritis etc; ethyl 1-(2-aminoethyl)-3-pyridin-4-yl-1H-pyrazole-5-carboxylate dihydrochloride
05/15/2008US20080113970 Transnasal anticonvulsive pharmaceutical composition
05/15/2008US20080113969 Administering allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating postoperative pain
05/15/2008US20080113968 Substituted piperazines and diazepanes
05/15/2008US20080113967 Enzyme modulators and treatments
05/15/2008US20080113966 CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine
05/15/2008US20080113965 Skeletal muscle protecting agent
05/15/2008US20080113964 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators
05/15/2008US20080113963 Prepared by submitting benzimidazole compound to a cyclization reaction; gastric secretion inhibiting and gastric and intestinal protective action properties; for gastrointestinal disorders; for example, 2,3-Dimethyl-8-phenyl-3,6,7,8-tetrahydro-chromeno[7,8-a]imidazole-5-carboxylic acid dimethylamide
05/15/2008US20080113962 Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders
05/15/2008US20080113961 Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds
05/15/2008US20080113960 Combinations comprising a low molecular weight thrombin inhibitor and a prodrug of a low molecular weight thrombin inhibitor
05/15/2008US20080113959 {Beta}-Lactamyl vasopression V1a antagonists and methods of use
05/15/2008US20080113958 Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings
05/15/2008US20080113957 azetidine-2-imines or fused ring derivatives thereof; inhibiting aspartyl proteases including beta-secretase; cardiovascular diseases, cognitive and neurodegenerative diseases such as Alzheimer's, inhibiting Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes
05/15/2008US20080113956 Substituted Porphyrins
05/15/2008US20080113955 Treatment of various patient populations at lower doses of stannsoporfin (tin (IV) mesoporphyrin IX dichloride) than previously believed effective, providing advantages in therapeutic administration; liver disorders
05/15/2008US20080113954 Supramolecular Metallic Complexes Exhibiting Both DNA Binding and Photocleavage
05/15/2008US20080113953 Administering ethinyl estradiol or prodrug thereof to patient with improved bioavailability by orally administering solid dosage form that releases effective amount of ethinyl estradiol or prodrug thereof in oral cavity for absorption through oral mucosa; for hormone replacement therapy or contraception
05/15/2008US20080113952 Combination Therapy For Treating Heart Disease
05/15/2008US20080113951 Administering in combination, a cyclooxygenase-2 inhibitor consisting of celecoxib or rofecoxib, low dose aspirin, and antioxidant flavonoids/isoflavones; synergistic; preventing thrombotic complications due to the long-term use of COX2 inhibitors
05/15/2008US20080113950 analgesic drug for treating neuropathic pain is selected from gabapentine, norvaline, pregabaline, (S)3-isobutylGABA, arginine, thiocitrulline, agmantine, vigabatrin etc. and a NO donar drugs belonging to the classes of aspirin, ibuprofen, paracetamol, naproxen, diclofenac or flurbiprofen
05/15/2008US20080113949 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention